Initial worsening following initiation of rituximab therapy in patients with cryoglobulinemic vasculitis was described in 3.6% of cases. This worsening is often a serious condition, with high levels of mortality. The objective of our study is to evaluate the efficacy of preventive plasmapheresis prior to the introduction of rituximab performed in Montpellier France since 2013 by assessing the frequency and severity of this flare effect in these patients compared to those reported in the literature.
Study Type
OBSERVATIONAL
Enrollment
120
Uhmontpellier
Montpellier, France
RECRUITINGcomparison of frequency of occurrence of flare effects
comparison of frequency of occurrence of flare effects between patients who received plasmapheresis prior to rituximab compared to patients who did not.
Time frame: 1 day
evaluation of the severity of the flare effect
evaluation of the severity of the flare effect
Time frame: 1 day
impact of known risk factors
investigation of the impact of known risk factors for this effect
Time frame: 1 day
evaluation of the safety of plasmapheresis in this indication
evaluation of the safety of plasmapheresis in this indication
Time frame: 1 day
evaluation of the efficacy of plasmapheresis on biological parameters
evaluation of the efficacy of plasmapheresis on biological parameters
Time frame: 1 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.